Veeva Unveils Clinical Trial Management System for Research Sites

Veeva Systems has announced the launch of Veeva SiteVault CTMS, a new clinical trial management system tailored for research sites. Integrated with SiteVault eISF and eConsent, the cloud-based software allows sites to manage clinical trials more efficiently through one unified platform.

The new CTMS enables bidirectional data flow with sponsors using Veeva's Clinical Platform, reducing manual tasks and streamlining communication. Scheduled for release in August 2025, SiteVault CTMS will be free for sites conducting up to 20 active studies.

Veeva positions this move as part of its mission as a Public Benefit Corporation, aiming to enhance research site operations and overall clinical trial efficiency. The system will be showcased at ACRP 2025 in New Orleans from April 24 to 27.

Veeva Systems Inc. Announces Board Changes
Pleasanton, CA – March 10, 2025 – Veeva Systems Inc. (NYSE: VEEV) announced that Tina Hunt has informed the Board of Directors of her intention to retire from her role as a director.

Effective Date: Immediately prior to the 2025 Annual Meeting of Shareholders
Impact: Dr. Hunt will not stand for re-election at the meeting.
Veeva thanks Dr. Hunt for her contributions and leadership during her tenure.

Veeva Reports Strong Fiscal Year 2025 Results with 16% Revenue Growth

Pleasanton, CA – March 5, 2025 – Veeva Systems Inc. (NYSE: VEEV), a leader in cloud solutions for the life sciences industry, has announced its fourth-quarter and fiscal year 2025 financial results, reporting total annual revenues of $2.75 billion, a 16% increase year-over-year. The company’s subscription services revenue grew by 20%, reaching $2.28 billion for the fiscal year.

In the fourth quarter, Veeva generated $720.9 million in revenue, reflecting a 14% growth from the same period last year. Subscription services revenue for Q4 was $608.6 million, marking a 17% increase. CEO Peter Gassner highlighted Veeva’s continued innovation in software, data, and business consulting, positioning the company for long-term growth in the life sciences sector.

Strong Financial Performance
Veeva reported significant improvements in profitability, with fiscal year operating income increasing by 61% to $691.4 million. On a non-GAAP basis, operating income for fiscal 2025 was $1.15 billion, up 37% year-over-year. Net income for the year stood at $714.1 million, a 36% increase, while non-GAAP net income rose 38% to $1.09 billion.

In Q4, Veeva’s operating income climbed 39% to $188.4 million, while non-GAAP operating income increased 29% to $307.7 million. Net income per share for the quarter was $1.18, compared to $0.90 in the previous year, and non-GAAP net income per share was $1.74, up from $1.38.

CFO Brian Van Wagener emphasized the company’s ability to exceed guidance across all key financial metrics, citing strong execution and momentum across Veeva’s product portfolio.

Key Business Highlights
Expanding Industry Cloud for Life Sciences – Veeva deepened strategic partnerships with top 20 biopharmas and emerging biotech firms, closing the year with 1,477 total customers across R&D and commercial solutions.
Vault CRM Adoption Accelerates – The December release of Vault CRM, featuring AI-driven innovations, saw strong adoption, with more than 50 customers already live and multiple firms migrating from legacy Veeva CRM.
Quality and Safety Solutions Gain Traction – 41 new customers adopted Veeva Quality Cloud, while major biopharma firms expanded their use of Veeva’s clinical, regulatory, and safety solutions.
With growing adoption across its solutions, Veeva remains well-positioned for continued innovation and strong financial performance in fiscal year 2026.